Timothy Hudson, MD
Cardiovascular Disease · Portland, ORNPI 1164516845
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,419 of the $7,546 with a category attached, or 85.1%. Medtronic accounts for 88.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $6,691 and has fallen 99.5% since, to $32 in 2024.
Across 38 payments — averaging $198.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Philips North America LLC$475
- Abiomed$230
- Boston Scientific$109
- Recor Medical Inc$32
- Edwards Lifesciences$28
What the payments were for
- Travel & lodging$6,41985%
- Food & beverage$1,12715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $6,671 |
| Philips North America LLC | 19 | $475 |
| Abiomed | 2 | $230 |
| Boston Scientific | 1 | $109 |
| Recor Medical Inc | 1 | $32 |
| Edwards Lifesciences | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$6,396
- Impella$137
- WATCHMAN Access System$109
How this compares
$7,546 in reported general payments places this provider in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 144 | $61,648 |
| EntrestoSacubitril/Valsartan | 13 | $10,288 |
| PradaxaDabigatran Etexilate Mesylate | 39 | $7,170 |
| Eplerenone | 20 | $4,851 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 75 | $2,147 |
| Spironolactone | 178 | $2,048 |
| Losartan Potassium | 80 | $886 |
| Nitroglycerin | 28 | $876 |
| Metoprolol Tartrate | 77 | $758 |
| Furosemide | 59 | $743 |
| Rosuvastatin Calcium | 64 | $701 |
| Carvedilol | 59 | $667 |
| Amlodipine Besylate | 45 | $606 |
| ClopidogrelClopidogrel Bisulfate | 37 | $555 |
| Flecainide Acetate | 13 | $475 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Portland
- Firas ZahrPortland$810K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Stephen HeitnerPortland$105K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
- Jeffrey MarbachPortland$19K
- Laith AlkukhunPortland$16K
- Tyler GluckmanPortland$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.